[Perspectives] Earliest evidence of malignant breast cancer in Renaissance paintings
In the ancient world, breast cancer estimates appear to be higher than those for any other types of cancer. Several potential cases of breast cancer during antiquity have been described in medical papers over the past millennia. However, a clear distinction between breast cancer and other non-malignant breast pathologies cannot be confidently made with the available evidence, and it is not possible to ascertain whether the estimates provided by ancient writers reflect the real incidence of the disease at the time. (Source: The Lancet Oncology)
Source: The Lancet Oncology - February 1, 2018 Category: Cancer & Oncology Authors: Raffaella Bianucci, Antonio Perciaccante, Philippe Charlier, Otto Appenzeller, Donatella Lippi Tags: Perspectives Source Type: research
[Perspectives] In search of Mangomoments
After waking up from coma in the intensive care unit (ICU), Viviane described how hard it was lying in bed all the time, what the grey ceiling looked like, how she heard the voices of deceased family members, and why she thought about euthanasia. Her reflections were captured in a documentary by a journalist who was an observer for 2 weeks at an ICU in a major teaching hospital. Following a tense silence, and being emotional as she was touched by Viviane's story, the journalist asked “Is there something I can do now for you, that would make you happy?”. (Source: The Lancet Oncology)
Source: The Lancet Oncology - February 1, 2018 Category: Cancer & Oncology Authors: Kris Vanhaecht Tags: Perspectives Source Type: research
[Corrections] Correction to Lancet Oncol 2017; 18: e713
Gourd E. Breast thermography alone no substitute for mammography. Lancet Oncol 2017; 18: e713 —The title of this News piece should have been “Breast thermography alone no substitute for mammography.” This correction has been made to the online version as of Jan 31, 2018. (Source: The Lancet Oncology)
Source: The Lancet Oncology - February 1, 2018 Category: Cancer & Oncology Tags: Corrections Source Type: research
[Corrections] Correction to Lancet Oncol 2017; 18: 1089 –103
Tap WD, Papai Z, Van Tine BA, et al. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2017; 18: 1089 –103—the affiliation of Giovanni Grignani was incorrect and should have been “Candiolo Cancer Institute, FPO, IRCCS, Turin, Italy”. This correction has been made to the online version as of Jan 31, 2018. (Source: The Lancet Oncology)
Source: The Lancet Oncology - February 1, 2018 Category: Cancer & Oncology Tags: Corrections Source Type: research
[Corrections] Correction to Lancet Oncol 2016; 17: e149 –62
Shaikh F, Murray MJ, Amatruda JF, et al. Paediatric extracranial germ-cell tumours. Lancet Oncol 2016; 17: e149 –62—The Acknowledgments have now been updated to include financial support from the St Baldrick's Foundation. These corrections have been made to the online version as of Jan 31, 2018. (Source: The Lancet Oncology)
Source: The Lancet Oncology - February 1, 2018 Category: Cancer & Oncology Tags: Corrections Source Type: research
[Correspondence] The Study of Letrozole Extension (SOLE) revisited
Several important questions and research considerations arise from the recent report by Marco Colleoni and colleagues.1 The study design of SOLE —4 consecutive years with a 3-month letrozole treatment interruption and a final year of continuous letrozole use (year 5), following completion of 4–6 years of adjuvant anti-oestrogen (tamoxifen or an aromatase inhibitor) therapy, versus 5 years of continuous letrozole—is really a test of pre planned noncompliance rather than an assessment of the therapeutic efficacy of oestrogen-induced apoptosis. (Source: The Lancet Oncology)
Source: The Lancet Oncology - February 1, 2018 Category: Cancer & Oncology Authors: V Craig Jordan Tags: Correspondence Source Type: research
[Correspondence] Use of olaparib in patients with advanced gastric cancer – Authors' reply
I thank Ji Zhu and colleagues for their interest in the GOLD study.1 (Source: The Lancet Oncology)
Source: The Lancet Oncology - February 1, 2018 Category: Cancer & Oncology Authors: Yung-Jue Bang Tags: Correspondence Source Type: research
[Correspondence] Use of olaparib in patients with advanced gastric cancer
We read with great interest the results from the GOLD study,1 which compared olaparib plus paclitaxel with placebo plus paclitaxel as second-line therapy for patients with advanced gastric cancer in a double-blind, randomised phase 3 setting. Despite the negative result, some aspects of the study warrant closer attention in comparison with the previous phase 2 trial (Study 39; NCT01063517), which showed a positive finding. (Source: The Lancet Oncology)
Source: The Lancet Oncology - February 1, 2018 Category: Cancer & Oncology Authors: Miao Mo, Jianing Yang, Xiaodong Zhu, Ji Zhu Tags: Correspondence Source Type: research
[Correspondence] Cancer in two Renaissance families
We have read the criticism of Philippe Charlier and colleagues1 regarding our letter about the presence of cancer at the Aragonese court of Naples,2 but we disagree with their conclusions. First, our brief report exclusively regarded the cases of malignant soft tissue tumours diagnosed by histology,3 which cannot be found in skeletons, and therefore we have not considered all bone cancer cases present in the literature. The number of soft tissue malignancies is still five, because the mentioned case of metastatic carcinoma in an Egyptian mummy was diagnosed only by CT,4 without histology. (Source: The Lancet Oncology)
Source: The Lancet Oncology - February 1, 2018 Category: Cancer & Oncology Authors: Gino Fornaciari, Valentina Giuffra Raffaele Gaeta Tags: Correspondence Source Type: research
[Correspondence] Young adults: a unique group in cancer epidemiological research – Authors' reply
We thank Olga Husson and colleagues for their comments and agree that a classification system tailored more specifically to this age group would reveal the importance of specific cancer forms commonly observed in childhood and adolescence. However, our primary objective was to present a comprehensive and representative analysis of the cancer burden among young adults worldwide.1 We used the International Agency for Research on Cancer's GLOBOCAN database,2 since incidence and mortality estimates are available for 184 countries classified according to the international standard for reporting diseases and health conditions (t...
Source: The Lancet Oncology - February 1, 2018 Category: Cancer & Oncology Authors: Miranda M Fidler, Eva Steliarova-Foucher, Isabelle Soerjomataram, Jacques Ferlay, Sumit Gupta, Freddie Bray Tags: Correspondence Source Type: research
[Correspondence] Young adults: a unique group in cancer epidemiological research
We read with great interest the results of the population-based study by Miranda Fidler and colleagues,1 quantifying the global cancer burden among young adults. The authors show that cancer incidence and mortality among 20 –39 year-olds differs from that of younger and older age groups. They also illustrate the heterogeneity of cancer types in young adults when stratified by age, sex, national development level, and geographical region. However, on the basis of the 10th revision of the International Classification o f Diseases (ICD-10), the authors describe the cancer burden of the 27 major cancer types in adults, resul...
Source: The Lancet Oncology - February 1, 2018 Category: Cancer & Oncology Authors: Olga Husson, Emma Lidington, Eugenie Younger, Winette TA van der Graaf Tags: Correspondence Source Type: research
[Correspondence] Negative phase 3 study of 90Y microspheres versus sorafenib in HCC – Authors' reply
We thank Takashi Kokudo and colleagues for their interest in our article and their positive comments. As these authors point out, the Barcelona Clinic Liver Cancer (BCLC) staging and treatment strategy recommends a single treatment for each clinical scenario and is not tailored to individual tumour and patient characteristics. We agree that biomarkers are needed to stratify patients for appropriate treatment. (Source: The Lancet Oncology)
Source: The Lancet Oncology - February 1, 2018 Category: Cancer & Oncology Authors: Val érie Vilgrain, Helena Pereira, Aurelia Dinut, Gilles Chatellier Tags: Correspondence Source Type: research
[Correspondence] Negative phase 3 study of 90Y microspheres versus sorafenib in HCC
It is with great interest that we read the report of the SARAH trial by Val érie Vilgrain and colleagues, recently published The Lancet Oncology.1 This paper reports the results of a large randomised phase 3 study in patients with advanced hepatocellular carcinoma (HCC), who showed no benefit in terms of overall survival after receiving yttrium-90 (90Y)-loaded resin micros phere selective internal radiation therapy (SIRT), as compared with sorafenib in an intention-to-treat approach. We believe at least three major adjustable elements could have contributed to the negativity of the trial. (Source: The Lancet Oncology)
Source: The Lancet Oncology - February 1, 2018 Category: Cancer & Oncology Authors: Etienne Garin, Yan Rolland, Boris Campillo-Gimenez, Julien Edeline Tags: Correspondence Source Type: research
[Correspondence] Negative phase 3 study of 90Y microspheres versus sorafenib in HCC
We read with interest the SARAH trial published in The Lancet Oncology.1 Two recently reported randomised controlled trials, the SARAH Trial1 and the SIRveNIb trial,2 were intended to show survival advantages comparing yttrium-90 (90Y) resin microsphere treatment with sorafenib in patients with advanced hepatocellular carcinoma (HCC). Both trials have been negative. We herein discuss the concept that failure to show superiority does not mean 90Y is equivalent to sorafenib, as the conclusion of the SARAH trial might indicate. (Source: The Lancet Oncology)
Source: The Lancet Oncology - February 1, 2018 Category: Cancer & Oncology Authors: Josep M Llovet, Richard S Finn Tags: Correspondence Source Type: research
[Correspondence] Negative phase 3 study of 90Y microspheres versus sorafenib in HCC
We read with great interest the article by Val érie Vilgrain and colleagues,1 reporting the results of a randomised controlled trial comparing sorafenib with selective internal radiotherapy (SIRT) in patients with locally advanced or intermediate-stage hepatocellular carcinoma (HCC) after unsuccessful transarterial chemoembolisation, and congra tulate the authors for their excellent work. Compared with sorafenib, SIRT did not improve overall or progression-free survival; however, it did significantly increase tumour response, reduce incidence of adverse events, and improve the quality of life. (Source: The Lancet Oncology)
Source: The Lancet Oncology - February 1, 2018 Category: Cancer & Oncology Authors: Takashi Kokudo, Norihiro Kokudo, Kiyoshi Hasegawa Tags: Correspondence Source Type: research
